Organon & Co (OGN)

Currency in USD
8.45
-0.26(-2.93%)
Real-time Data·
Earnings results expected in 15 days
OGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.388.76
52 wk Range
5.6913.25
Key Statistics
Prev. Close
8.7
Open
8.7
Day's Range
8.38-8.76
52 wk Range
5.69-13.25
Volume
1.77M
Average Vol. (3m)
5.46M
1-Year Change
-23.5294%
Book Value / Share
2.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.00
Upside
+6.51%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Organon & Co News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Employees
10000

Organon & Co SWOT Analysis


Analyst Outlook
Discover why analysts maintain an "Overweight" rating for Organon, with price targets ranging from $24 to $26, despite current stock price pressures
Strategic Expansion
Learn about Organon's diversification strategy, including the acquisition of VTAMA and its potential $500 million sales target in the dermatology market
Financial Health
Delve into Organon's profitability metrics, including a 57.2% gross profit margin, and analyst projections of steady EPS growth for upcoming fiscal years
Market Resilience
Explore Organon's robust performance in women's health and biosimilars, with Nexplanon and Hadlima driving growth despite market challenges
Read full SWOT analysis

Organon & Co Earnings Call Summary for Q4/2025

  • Organon reported Q4 2025 EPS of $0.63, missing forecasts of $0.76, with revenue of $1.51B below expected $1.54B, resulting in a 10.79% stock drop
  • The company posted a Q4 net loss of $205M while achieving over $200M in cost savings and retiring $530M in debt during 2025
  • Full-year 2025 revenue declined 3% to $6.2B, with adjusted EBITDA at $1.9B, despite 61% global revenue growth in biosimilar Hadlima
  • For 2026, management projects flat revenue and adjusted EBITDA compared to 2025, with expected gross margin deterioration of 75-100 basis points
  • Interim CEO Joe Morrissey emphasized maintaining performance levels, while the company continues to face competitive pressures in biosimilars and fertility markets
Last Updated: 02/12/2026, 09:24 AM
Read Full Transcript
Organon Co investor slides for Q4/2025
Organon Q4 2025 slides
Last Update: Feb 12, 2026
See full investor slides

Compare OGN to Peers and Sector

Metrics to compare
OGN
Peers
Sector
Relationship
P/E Ratio
11.9x13.5x−0.5x
PEG Ratio
−0.15−1.710.00
Price / Book
3.0x1.2x2.6x
Price / LTM Sales
0.4x2.0x3.2x
Upside (Analyst Target)
3.4%24.8%47.6%
Fair Value Upside
Unlock25.1%6.1%Unlock

Analyst Ratings

1 Buy
3 Hold
4 Sell
Ratings:
8 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 9.00
(+6.51% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Sell8.00-5.44%7.50MaintainFeb 24, 2026
Barclays
Sell7.50-11.35%-New CoverageDec 09, 2025
Morgan Stanley
Hold9.00+6.38%10.00MaintainNov 11, 2025
JPMorgan
Sell12.00+41.84%14.00MaintainNov 11, 2025
Piper Sandler
Sell5.00-40.90%18.00DowngradeOct 27, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.72%
Dividend Yield
0.94%
Industry Median 2.36%
Annualized Payout
0.08
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 12, 2026
EPS / Forecast
0.63 / 0.76
Revenue / Forecast
1.51B / 1.54B
EPS Revisions
Last 90 days

OGN Income Statement

People Also Watch

33.930
PL
0.00%
826.10
LITE
-3.13%
885.03
SNDK
-6.29%
398.93
AXON
+4.74%
387.16
INTU
+5.55%

FAQ

What Is the Organon Co (OGN) Stock Price Today?

The Organon Co stock price today is 8.45 USD.

What Stock Exchange Does Organon Co Trade On?

Organon Co is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Organon Co?

The stock symbol for Organon Co is "OGN."

Does Organon Co Pay Dividends? What’s The Current Dividend Yield?

The Organon Co dividend yield is 0.92%.

What Is the Organon Co Market Cap?

As of today, Organon Co market cap is 2.20B USD.

What Is Organon Co's Earnings Per Share (TTM)?

The Organon Co EPS (TTM) is 0.72.

When Is the Next Organon Co Earnings Date?

Organon Co will release its next earnings report on Apr 30, 2026.

From a Technical Analysis Perspective, Is OGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Organon Co Stock Split?

Organon Co has split 0 times.

How Many Employees Does Organon Co Have?

Organon Co has 10000 employees.

What is the current trading status of Organon Co (OGN)?

As of Apr 15, 2026, Organon Co (OGN) is trading at a price of 8.45 USD, with a previous close of 8.70 USD. The stock has fluctuated within a day range of 8.38 USD to 8.76 USD, while its 52-week range spans from 5.69 USD to 13.25 USD.

What Is Organon Co (OGN) Price Target According to Analysts?

The average 12-month price target for Organon Co is 9.00 USD, with a high estimate of 12 USD and a low estimate of 5 USD. 1 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +6.51% Upside potential.

What Is the OGN Premarket Price?

OGN's last pre-market stock price is 8.66 USD. The pre-market share volume is 29,620.00, and the stock has decreased by -0.04, or -0.46%.

What Is the OGN After Hours Price?

OGN's last after hours stock price is 8.65 USD, the stock has decreased by -0.05, or -0.57%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.